GCC Generic Injectables Market Report by Container Type (Vials, Prefilled Syringes, Ampoules, Premix, and Others), Therapeutic Area (Oncology, Anaesthesia, Anti-infectives, Cardiovascular, Parenteral Nutrition, and Others), Distribution Channel (Hospitals, Clinics, Retail Pharmacy Stores), and Region 2024-2032

GCC Generic Injectables Market Report by Container Type (Vials, Prefilled Syringes, Ampoules, Premix, and Others), Therapeutic Area (Oncology, Anaesthesia, Anti-infectives, Cardiovascular, Parenteral Nutrition, and Others), Distribution Channel (Hospitals, Clinics, Retail Pharmacy Stores), and Region 2024-2032

Report Format: PDF+Excel | Report ID: SR112024A1005
Buy Now

Market Overview:

The GCC generic injectables market size reached US$ 685.0 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,814.4 Million by 2032, exhibiting a growth rate (CAGR) of 11.1% during 2024-2032. The growing investment by pharmaceutical companies in marketing innovative drugs, less approval time, and domestic manufacturing in the GCC region represent some of the key factors driving the market.

Report Attribute 
Key Statistics
Base Year
2023
Forecast Years
2024-2032
Historical Years
2018-2023
Market Size in 2023
US$ 685.0 Million
Market Forecast in 2032
US$ 1,814.4 Million
Market Growth Rate 2024-2032 11.1%


Rising Prevalence of Chronic Diseases Impelling Market Growth

The growing population and rising occurrence of chronic diseases and non-communicable diseases (NCDs) currently represent one of the primary factors driving the sales of generic injectables in the GCC region. With the growing geriatric population in the region, the deaths and disabilities caused due to NCDs are rising. High-valued patented injectables add more cost, whereas generic injectables do the same job at a lower price, thereby making them affordable to maximum patients.

Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. The market structure is fragmented with a number of global and regional players operating in the industry. The volume of new entrants is moderate in the GCC generic injectables industry as the high market growth and low product differentiation and switching costs, attract new entrants to enter the market. However, high capital investment prevents new entrants from foraying into the industry.

What are Generic Injectables?

Generic injectables are pharmaceutical drugs which are equivalent to brand-name injectables with respect to dosage, strength, route of administration, quality, performance, and intended use. These injectables are made available in the market after the patent expiration of branded injectables. They undergo complex manufacturing processes, but cheaper and shorter research and development (R&D) cycles as compared to branded injectables. Generic injectables are less expensive than branded injectables and, thereby contribute to significant savings for patients and healthcare providers. They are widely used in the treatment of various chronic diseases, such as cancer, diabetes, cardiovascular diseases, respiratory diseases, rheumatoid arthritis, osteoarthritis, and osteoporosis.

COVID-19 Impact:

The rapid spread of COVID-19 in the GCC countries has adversely impacted various businesses across the region. In order to slow down the spread, governing agencies in the region have taken various measures, including the closing of borders, suspension of air traffic, and imposition of a comprehensive quarantine. The rapid spread of the virus has negatively impacted both the supply and demand across the region. Supply chain disruptions, reduced availability of raw materials, factory shutdowns, and trade bans are some of the major factors that have impacted the supply. The outbreak of COVID-19 has also impacted supply chains in the GCC pharmaceutical industry. This was true not only for finished products but also for raw materials. The countries in the GCC region were facing interruptions in the supply of generic drugs as the majority of the generic drug demand in the region were fulfilled by imports. Logistics services were the primary reason for this disruption. As a consequence of this, countries in the region, especially Saudi Arabia and UAE, were fostering the localization and encouraging local production of generic drugs to reduce the impact of any disruptions. This, in turn, is expected to provide a positive impetus to the GCC generic injectables sector.

GCC Generic Injectables Market Trends:

At present, the rising demand for generic injectables on account of the high affordability, as they do not require extensive research and testing and saves both money and time, represents one of the key factors supporting the growth of the market in the GCC region. Besides this, generic injectables require lower capital investment compared to patented injectables, as key manufacturers do not invest in drug discovery and various clinical trials since it is previously verified for the patented injectable, which is impelling the growth of the market in the region. In addition, the growing demand for generic injectables due to less approval time is offering a favorable market outlook in the GCC region. Moreover, the increasing investment by pharmaceutical companies in marketing innovative drugs, as they need to educate both physicians and authorities on the efficacy and safety profile of new drugs, is strengthening the growth of the market. Apart from this, governing agencies in the GCC region are encouraging domestic manufacturing of generic injectables, which is offering lucrative growth opportunities to industry investors. Additionally, the growing prevalence of acute and chronic disease cases due to the rising emigrant population in the region is positively influencing the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the GCC generic injectables market report, along with forecasts at the regional and country level from 2024-2032. Our report has categorized the market based on container type, therapeutic area and distribution channel.

Container Type Insights:

  • Vials
  • Prefilled Syringes
  • Ampoules
  • Premix
  • Others
     

The report has provided a detailed breakup and analysis of the GCC generic injectables market based on the container type. This includes vials, prefilled syringes, ampoules, premix, and others. According to the report, vials represented the largest segment, as they are small glasses or plastic vessels, often used to store medication in several forms, such as liquids, powders, or capsules. In addition, the growing demand for vials due to the lower risk of breakage and contamination is offering a favorable market outlook.

Therapeutic Area Insights:

  • Oncology
  • Anaesthesia
  • Anti-infectives
  • Cardiovascular
  • Parenteral Nutrition
  • Others
     

A detailed breakup and analysis of the GCC generic injectables market based on the therapeutic area has also been provided in the report. This includes oncology, anaesthesia, anti-infectives, cardiovascular, parenteral nutrition, and others. According to the report, oncology accounted for the largest market share due to the rising prevalence of cancer in the region. Moreover, various government and non-government organizations are promoting the manufacturing of generic oncology injectables to provide treatment to the maximum number of people at affordable rates.

Distribution Channel Insights:

  • Hospitals
  • Clinics
  • Retail Pharmacy Stores
     

A detailed breakup and analysis of the GCC generic injectables market based on the distribution channel has also been provided in the report. This includes hospitals, clinics, and retail pharmacy stores. According to the report, hospitals accounted for the largest market share, as injectables cannot be traded without prescription from a certified practitioner due to stringent regulations in the GCC countries. Moreover, the rapid increase in non-communicable diseases (NCDs) has prompted investments in specialized hospitals and clinics with advanced technologies and improved capabilities.

Regional Insights:

  • Saudi Arabia
  • UAE
  • Kuwait
  • Qatar
  • Oman
  • Bahrain
     

The report has also provided a comprehensive analysis of all the major regional markets, which include Saudi Arabia, UAE, Kuwait, Qatar, Oman, and Bahrain. According to the report, Saudi Arabia was the largest market for GCC generic injectables. Some of the factors driving the Saudi Arabia generic injectables market included the growing domestic generic injectable manufacturing base, rising prevalence of chronic diseases, and new product launches. In addition, the increasing healthcare expenditure, along with favorable government initiatives, is offering lucrative growth opportunities to industry investors. Moreover, the transition of public hospitals to an increasingly privatized and comprehensive healthcare system in Saudi Arabia is catalyzing the demand for generic injectables.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the GCC generic injectables market.

Report Coverage:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units US$ Million
Segment Coverage Container Type, Therapeutic Area, Distribution Channel, Country
Countries Covered Saudi Arabia, UAE, Kuwait, Qatar, Oman, Bahrain
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 3699
Five User License: US$ 4699
Corporate License: US$ 5699
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


Key Benefits for Stakeholders:

  • IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the GCC generic injectables market from 2018-2032.
  • The research study provides the latest information on the market drivers, challenges, and opportunities in the GCC generic injectables market.
  • The study maps the leading, as well as the fastest-growing, regional markets.
  • Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the GCC generic injectables industry and its attractiveness.
  • Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.

Key Questions Answered in This Report

The GCC generic injectables market was valued at US$ 685.0 Million in 2023.

We expect the GCC generic injectables market to exhibit a CAGR of 11.1% during 2024-2032.

The rising prevalence of various chronic diseases, such as cancer, diabetes, osteoporosis, rheumatoid arthritis, etc., along with the increasing adoption of generic injectables, as they are cost-effective and offer enhanced patient outcomes, is primarily driving the GCC generic injectables market.

The sudden outbreak of the COVID-19 pandemic has led to the growing demand for generic injectables across several GCC nations, owing to the introduction of self-injection devices to reduce the risk of the coronavirus infection upon hospital visits or interaction with healthcare professionals.

Based on the container type, the GCC generic injectables market can be segmented into vials, prefilled syringes, ampoules, premix, and others. Currently, vials hold the majority of the total market share.

Based on the therapeutic area, the GCC generic injectables market has been divided into oncology, anesthesia, anti-infectives, cardiovascular, parenteral nutrition, and others. Among these, oncology currently exhibits a clear dominance in the market.

Based on the distribution channel, the GCC generic injectables market can be segregated into hospitals, clinics, and retail pharmacy stores. Currently, hospitals account for the largest market share.

On a regional level, the market has been classified into Saudi Arabia, UAE, Kuwait, Qatar, Oman, and Bahrain, where Saudi Arabia currently dominates the GCC generic injectables market.

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
GCC Generic Injectables Market Report by Container Type (Vials, Prefilled Syringes, Ampoules, Premix, and Others), Therapeutic Area (Oncology, Anaesthesia, Anti-infectives, Cardiovascular, Parenteral Nutrition, and Others), Distribution Channel (Hospitals, Clinics, Retail Pharmacy Stores), and Region 2024-2032
Purchase options




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARTI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More